Resultados de Búsqueda por Autor

1

artículo

Co-infection with Bartonella bacilliformis and Mycobacterium spp. in a coastal region of Peru

Publicado por
Silva-Caso W., Mazulis F., Weilg C., Aguilar-Luis M.A., Sandoval I., Correa-Nuñez G., Li D., Song X., Liu Q., Del Valle-Mendoza J.

Publicado 2017

Enlace

Objective: This study investigated an outbreak of Bartonellosis in a coastal region in Peru.Results: A total of 70 (n = 70) samples with clinical criteria for the acute phase of Bartonellosis and a positive peripheral blood smear were included. 22.85% (n = 16) cases of the samples were positive for Bartonella bacilliformis by PCR and automatic sequencing. Of those positive samples, 62.5% (n = 10) cases were positive only for B. bacilliformis and 37.5% (n = 6) cases were positive to both Mycobacterium spp. and B. bacilliformis. The symptom frequencies were similar in patients diagnosed with Carrion's disease and those co-infected with Mycobacterium spp. The most common symptoms were headaches, followed by malaise and arthralgia.

2

artículo

Molecular identification of Bartonella bacilliformis in ticks collected from two species of wild mammals in Madre de Dios: Peru

Publicado por
Del Valle-Mendoza J., Rojas-Jaimes J., Vásquez-Achaya F., Aguilar-Luis M.A., Correa-Nuñez G., Silva-Caso W., Lescano A.G., Song X., Liu Q., Li D.

Publicado 2018

Enlace

ObjectiveTo study the presence of Bartonella bacilliformis in ticks collected from two wild mammals in Madre de Dios, Peru.ResultsA total of 110 ticks were collected. Among the 43 Amblyomma spp. extracted from the 3 Tapirus terrestris only 3 were positive for B. bacilliformis. In addition, 12 out of the 67 Rhipicephalus (Boophilus) microplus obtained from the 3 Pecari tajacu were positive for B. bacilliformis. For the first time B. bacilliformis have been detected in arthropods other than Lutzomyia spp. Further studies are required to elucidate the possible role of ticks in the spread of South American Bartonellosis.

3

artículo

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Publicado por
Sun, JM, Shen, L, Shah, MA, Enzinger, P, Adenis, A, Doi, T, Kojima, T, Metges, JP, Li, Z, Kim, SB, Cho, BC, Mansoor, W, Li, SH, Sunpaweravong, P, Maqueda, MA, Goekkurt, E, Hara, H, Antunes, L, Fountzilas, C, Tsuji, A, Castro-Oliden, V, Liu Q, Shah S, Bhagia P, Kato K, KEYNOTE-590 Investigators.

Publicado 2021

Enlace

Background: First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced oesophageal cancer and Siewert type 1 gastro-oesophageal junction cancer. Methods: We did a randomised, placebo-controlled, double-blind, phase 3 study across 168 medical centres in 26 countries. Patients aged 18 years or older with previously untreated, histologically or cytologically confirmed, locally advanced, unresectable or metastatic oesophageal cancer or Siewert type 1 gastro-oesophageal junction cancer (regardless of PD-L1 status), measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1, and Eastern Cooperative Oncology Group performance status of 0-1, were randomly assigned (1:1)...